Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

nAChRs are the focus of intense drug discovery efforts for the treatment of several nervous-system disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, depression and ...

Certain groups, including people diagnosed with human immunodeficiency virus (HIV), need to be aware of their higher risk for tuberculosis. COVID-19 is a disease caused by ... histamines that can ...

“Medication adherence and discontinuation present a major challenge in the treatment of schizophrenia and schizoaffective disorder,” said Rongbing Yang, President of Luye Pharma Group.

Respiratory virus data included in the interactive data application is up-to-date as of April 12, 2025. Among its new features, the dashboard now includes RSV Severe Outcomes data.

2 University of Manitoba, Department of Pediatrics, Section of Allergy and Clinical Immunology, Winnipeg, MB 3 University of British Columbia, Department of Pediatrics, Division of Allergy and ...

Immunization is the best way to protect against respiratory syncytial virus (RSV) infections and their complications. It involves administering a preventive treatment or vaccine to help the body ...

Coronavirus and respiratory syncytial virus (RSV) are two kinds ... People over 65 Those with a weakened immune system Those with heart or lung diseases RSV doesn't usually come with long-term ...